LOGIN  |  REGISTER
Chimerix
Compass Therapeutics

Ocumetics Technology Announces Corporate Changes

May 01, 2025 | Last Trade: C$1.08 0.00 0.00

Calgary, AlbertaTheNewswire - May 1, 2025 - Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) (the “Corporation” or “Ocumetics”) announces that Mr. Dayton Marks has resigned as a director of the Corporation.

“On behalf of the Ocumetics board of directors, I would like to thank Dayton for his contributions to Ocumetics,” said Dr. Garth Webb, Ocumetics’ Founder and Chairman of the Board. “We are thankful for his significant efforts and contributions to the Corporation. We wish him well in his future endeavours.”

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.  

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns                                

President and CEO                        

(817) 874-7564           

Roger Jewett        

Chief Financial Officer            

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

  

Chimerix

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page